Optimisation and modelling of anaerobic digestion of whiskey distillery/brewery wastes after combined chemical and mechanical pre-treatment

Whiskey distillery waste streams consisting of pot ale (liquid residue) and spent grain (solid residue) are high strength organic wastes and suitable feedstock for anaerobic digestion (AD) from both economic and environmental stand points. Anaerobic digestion of pot ale and pot ale/spent grain mixtures (with mixing ratios of 1:1, 1:3, and 1:5 by wet weight) was performed after implementation of a novel hybrid pre-treatment (combined chemical and mechanical) in order to modify lignocellulosic structure and ultimately enhance digestion yield. Lignin, hemicellulose, and cellulose fractions were determined before and after chemical pre-treatment. Effects of different inoculum rates (10–30–50% on wet basis) and beating times (0–7.5–15 min) on anaerobic digestion of pot ale alone and of pot ale/spent grain mixtures were investigated in lab scale batch mode with a major focus of optimising biogas yield by using response surface methodology (RSM) in Design Expert Software. The highest biogas yields of 629 ± 8.5 mL/g vs. (51.3% CH4) and 360 ± 10 mL/g vs. (55.0 ± 0.4) with anaerobic digestion of pot ale alone and spent grain mix after 1M NaOH and 7.5 min beating pre-treatments with 50% inoculum ratio respectively. The optimum digestion conditions to maximise the biogas quality and quantity were predicted as 10 and 13 min beating times and 32 and 38 ◦C digestion temperatures for anaerobic digestion of pot ale alone and spent grain mix respectively

Coral assemblages at higher latitudes favor short-term potential over long-term performance

Funding for this research was provided by a Natural Environment Research Council (NERC) Doctoral Training Programme Scholarship to JC, a Royal Geographical Society Ralph Brown Expedition Award (RBEA 03/19) to MB and JC, the Australian Research Council Centre of Excellence for Coral Reef Studies (CE140100020) to JMP and others, the Australian Research Council Centre of Excellence for Environmental Decisions (CE110001014), a British Ecological Society small grant, the Winifred Violet Scott Charitable Trust, and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement TRIM-DLV-747102 to MB. BS was supported by an Australian Research Council Discovery Early CareerResearch Award (DE230100141), a University of Sydney Fellowship and a Chancellor’s Postdoctoral Research Fellowship from the University of Technology Sydney.The persistent exposure of coral assemblages to more variable abiotic regimes is assumed to augment their resilience to future climatic variability. Yet, while the determinants of coral population resilience across species remain unknown, we are unable to predict the winners and losers across reef ecosystems exposed to increasingly variable conditions. Using annual surveys of 3171 coral individuals across Australia and Japan (2016-2019), we explore spatial variation across the short- and long-term dynamics of competitive, stress-tolerant, and weedy assemblages to evaluate how abiotic variability mediates the structural composition of coral assemblages. We illustrate how, by promoting short-term potential over long-term performance, coral assemblages can reduce their vulnerability to stochastic environments. However, compared to stress-tolerant, and weedy assemblages, competitive coral taxa display a reduced capacity for elevating their short-term potential. Accordingly, future climatic shifts threaten the structural complexity of coral assemblages in variable environments, emulating the degradation expected across global tropical reefs.Publisher PDFPeer reviewe

(Post-)queer citizenship in contemporary republican France

1996 saw the publication of Frédéric Martel’s Le Rose et le noir, a comprehensive study of three decades of gay life in metropolitan France. The predominantly anti-communitarian stance adopted by Martel in the epilogue to the first edition of his work had evolved, by the time of the book’s publication en poche in 2000, into a more nuanced view of the interactions and intersections between queer and republican identities in contemporary France. This development was influenced, in large part, by concrete changes which took place over the second half of the 1990s, centring around the introduction of the PACS in 1999, and leading to an ever-broadening debate. This paper will begin by setting forth the ways in which Martel’s position changed and analysing the attitudinal, social, and legislative backdrop which paved the way for such a change to occur. It will then bring Martel’s work into a dialogue with the writings of Eric Fassin and Maxime Foerster, both of whom have, like Martel, offered crucial analyses of the place of queer citizens within the contemporary French republic. Particular attention will first be paid to the ways in which Fassin, in his writings, has underlined the salience of the ‘droit du sol/droit du sang’ debate, traditionally associated with questions of ethnic belonging, in light of public and political discussions revolving around questions of queer kinship raised by the introduction of the PACS. This will lead into an examination of Foerster’s assertion that gay citizens of the Republic, in the era of the PACS, find themselves in a role previously held by women, in other words, as elements that require integration within a republican model. Foerster argues that this requirement to integrate is indicative of the fact that the traditional republican claim that the citizen is a blank canvas is at best misguided, and, at worst, has been deliberately subverted. This paper will examine the manner in which Martel and Fassin’s observations can be used to further strengthen the points raised by Foerster, concluding with the latter that a true engagement with the issues raised by debates around queer citizenship over the past decade can, in fact, allow the contemporary republican citizen to ‘devenir ceux [qu’il] est’. In other words, the article will conclude that the potential impact of the PACS legislation and the broader discussions it has provoked could be a renegotiation of the relationship between queer citizens and the republic

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Transanal Irrigation in Children: Treatment Success, Quality of Life, Adherence, Patient Experience, and Independence

Objectives: To investigate the clinical effectiveness and patient experience of transanal irrigation (TAI) in children with constipation or fecal incontinence. Methods: Combined retrospective and cross-sectional study including pediatric patients who used a Navina TAI system. We retrospectively collected baseline characteristics and data on treatment success at 1- and 6-month follow-up (FU). Treatment success was defined as defecating at least 3 times per week and having less than 1 episode of fecal incontinence per week. We cross-sectionally assessed health-related quality of life (HRQoL), treatment adherence, treatment satisfaction (Treatment Satisfaction Questionnaire for Medication [TSQM]), illness perceptions, medication beliefs, and patient empowerment with validated questionnaires. Results: Thirty-four patients were included (median age at start TAI: 11 years old [range, 6-18]), 32 in the retrospective review, and 26 in the cross-sectional survey (median of 3 years after initiation). Most patients were diagnosed with functional constipation (n = 26; 76%) or a neurogenic bowel disorder (n = 6; 18%). Treatment success rates significantly improved at each FU compared with baseline (baseline: 4/25 [16%]; 1-month FU: 12/16 [75%], P = 0.008; 6-month FU: 11/18 [61%], P = 0.016; cross-sectional FU: 13/26 [50%], P = 0.008). HRQoL scores were high (PedsQL median, 73 [IQR, 54-85]). Adherence (defined as Medication Adherence Report Scale [MARS] ≥ 23) was low (36%), whereas TSQM effectiveness scores were high (median, 69 [IQR, 47-86]). The majority of children (61%) reported an increase in independence since TAI treatment. Patient empowerment (GYPES) levels were similar to those reported in children with other chronic conditions. Conclusions: TAI with a Navina system is an effective bowel management system for children with intractable constipation or fecal incontinence